Recipients who received 2nd Covid booster with a longer than recommended interval from 1st immunization had improved specific antibody response, but asimilar T cell response. This differential effect was nullified by a 3rdbooster. “Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters” JI Ahmed, CM Card, et al. […]

“Is one lymphocyte’s brake another lymphocyte’s gas?” Thomas T Xu, Shiv Pillai. (Feb 7, 2025) Sci Immunol 10(104): eadw3656 doi: 10.1126/sciimmunol.adw365 PMID: 39919195 PD-1 (CD279) binding to its ligand PD-L1 (CD274) is down regulatory for T cell immune response in the context of cancer. However, studies are showing that this interaction is required for development

Cyclophilin A is a ligand for RAGE in thrombo-inflammation Peter Seizer, David Heinzmann, et al. (March 2024) Cardiovascular Research 120(4): 385–402, https://doi.org/10.1093/cvr/cvad189 Ancell anti-human CD147 mAb was used for detection and to block activation of cells by Cyclophilan A Related Ancell Products anti-human CD147( EMMPRIN) mAb

“Non Classical” (CCR2+ CD16++ CD14+ MHC Class II+ CD209+) subset of mouse monocytes were expanded using NOD2 small-molecule activators. CCR2 enabled these cells to infiltrate tumors and inhibit metastasis in mouse models of colon, lung, breast and melanoma through CCL6 recruitment of NK cells. The monocyte CCR2/CCL2 axis merits further investigation for cancer intervention! “Inducible

Levels of LTbR (Lymphotoxin beta Recpeptor) on TAM (Tumor Associated Macrophage) inversely correlate with anti-tumor response, indicating an immunosuppresive role. This Chinese research group demonstrate that disrupting this expression in mice by silencing or knockout causes tumor regression in a mouse lung carcinoma model. “LTBR acts as a novel immune checkpoint of tumor-associated macrophages for

This Korean research group screened mAbs generated against Multiple Myeloma and developed a mAb (clone NPB15) specific to an epitope of CD98 present on stem and cancer cells, but not on CD98 presented by more differentiated tissues. They demonstrated the therapeutic potential of this mAb. “A monoclonal antibody recognizing CD98 on human embryonic stem cells

“Cyclophilin A is a ligand for RAGE in thrombo-inflammation” P Seizer, D Heinzmann, et al. Cardiovascular Research (2024) 120: 385-402. https://doi.org/10.1093/cvr/cvad189 PMID: 38175781 Ancell anti-CD147 antibody (clone UM-8D6) was used to block monocyte chemotaxis, induce NfkB translocation and to stimulate MyD88 antigen upregulation in monocytes. Ancell anti-CD147 mAb products

“Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization” DC Chung, PS Ohashi, et al. J Immunol(2024) 212(12): 1904-1912. https://doi.org/10.4049/jimmunol.2300834 PMID: 38668728 This Toronto based research group used a combination of TGF-b1 and IL-15 to induce a CD103+/CD49a+ phenotype in peripheral blood derived NK cells. Co incubation with this NK cell line inhibited CD4

Ancell mAbs were used by this Cal State Research group to block trogocytic killing of Triconomas Vaginelas parasite by human PLB-95 Neutrophil-Like-cells in vitro. Blocking CD11c and CD18 receptors on NLC with antibodies resulted in significant reduction of killing, implicting CR3 mediated complement fixation as the primary mechanism. “Complement receptor 3 is required for maximum

Russian Researchers investigating Redox processes in Neutrophil activation. “Redox processes are major regulators of leukotriene synthesis in neutrophils exposed to bacteria Salmonella typhimurium; the way to manipulate neutrophil swarming” E A Golenkina, G F Sud’ina, et al. (Feb 2024) Front. Immunol 15 (06 February 2024) PMID: 38384456 PMCID: PMC10880102 DOI: 10.3389/fimmu.2024.1295150 . Relevant Ancell Products